Crizotinib.
AT Shaw, U Yasothan… - Nature reviews Drug …, 2011 - search.ebscohost.com
AT Shaw, U Yasothan, P Kirkpatrick
Nature reviews Drug discovery, 2011•search.ebscohost.comAbstract In August 2011 crizotinib (Xalkori; Pfizer), a small-molecule kinase inhibitor, was
approved by the US Food and Drug Administration (FDA) for the treatment of patients with
locally advanced or metastatic non-small-cell lung cancer that is anaplastic lymphoma
kinase-positive, as detected by an FDA-approved test.
approved by the US Food and Drug Administration (FDA) for the treatment of patients with
locally advanced or metastatic non-small-cell lung cancer that is anaplastic lymphoma
kinase-positive, as detected by an FDA-approved test.
Abstract In August 2011 crizotinib (Xalkori; Pfizer), a small-molecule kinase inhibitor, was approved by the US Food and Drug Administration (FDA) for the treatment of patients with locally advanced or metastatic non-small-cell lung cancer that is anaplastic lymphoma kinase-positive, as detected by an FDA-approved test.
search.ebscohost.com